SETTING: Tuberculosis units (Beatrixoord, Haren; and Dekkerswald, Groesbeek) in the Netherlands. OBJECTIVE: To study the long-term treatment outcome of patients with multidrug-resistant tuberculosis (MDR-TB). DESIGN: Descriptive analysis of all consecutively admitted patients with MDR-TB between 1 January 1985 and 1 September 1998, with follow-up until 1 August 1999. RESULTS: Of 44 patients (31 male) enrolled in the study, 33 were foreign born and none were human immunodeficiency virus positive. At diagnosis 38 patients had sputum-smear positive pulmonary TB, and converted culture negative after a mean of 6 weeks, while six converted to negative later (mean 69 weeks). Most patients had micro-organisms resistant to several antimycobacterial drugs (mean = median: 5), including resistance to isoniazid and rifampin. In-patient treatment lasted a mean of 164 days (range 31-481), and patients were treated with six drugs on average. Side effects were common. Treatment lasted for a mean of 608 days (range 268-1626); five patients are still on treatment. Four patients were operated for TB, and two others were operated for post-TB sequelae. During the follow-up period six patients died, of whom three had active TB; 33 (75%) were considered cured. CONCLUSION: Mortality was only 14% after a mean follow-up period of 53 months. MDR-TB can be successfully treated, but requires much effort from both patients and carers, and the costs may be higher than is affordable in resource-poor countries.
SETTING:Tuberculosis units (Beatrixoord, Haren; and Dekkerswald, Groesbeek) in the Netherlands. OBJECTIVE: To study the long-term treatment outcome of patients with multidrug-resistant tuberculosis (MDR-TB). DESIGN: Descriptive analysis of all consecutively admitted patients with MDR-TB between 1 January 1985 and 1 September 1998, with follow-up until 1 August 1999. RESULTS: Of 44 patients (31 male) enrolled in the study, 33 were foreign born and none were human immunodeficiency virus positive. At diagnosis 38 patients had sputum-smear positive pulmonary TB, and converted culture negative after a mean of 6 weeks, while six converted to negative later (mean 69 weeks). Most patients had micro-organisms resistant to several antimycobacterial drugs (mean = median: 5), including resistance to isoniazid and rifampin. In-patient treatment lasted a mean of 164 days (range 31-481), and patients were treated with six drugs on average. Side effects were common. Treatment lasted for a mean of 608 days (range 268-1626); five patients are still on treatment. Four patients were operated for TB, and two others were operated for post-TB sequelae. During the follow-up period six patients died, of whom three had active TB; 33 (75%) were considered cured. CONCLUSION: Mortality was only 14% after a mean follow-up period of 53 months. MDR-TB can be successfully treated, but requires much effort from both patients and carers, and the costs may be higher than is affordable in resource-poor countries.
Authors: J W C Alffenaar; T van der Laan; S Simons; T S van der Werf; P J van de Kasteele; H de Neeling; D van Soolingen Journal: Antimicrob Agents Chemother Date: 2011-01-03 Impact factor: 5.191
Authors: Anne F Luetkemeyer; Haileyesus Getahun; Gabriel Chamie; Christian Lienhardt; Diane V Havlir Journal: Am J Respir Crit Care Med Date: 2011-08-25 Impact factor: 21.405
Authors: Jan-Willem C Alffenaar; Richard van Altena; Ilse M Harmelink; Patricia Filguera; Esther Molenaar; A Mireille A Wessels; Dick van Soolingen; Jos G W Kosterink; Donald R A Uges; Tjip S van der Werf Journal: Clin Pharmacokinet Date: 2010-08 Impact factor: 6.447
Authors: Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies Journal: Eur Respir J Date: 2012-10-25 Impact factor: 16.671
Authors: Mayara L Bastos; Hamidah Hussain; Karin Weyer; Lourdes Garcia-Garcia; Vaira Leimane; Chi Chiu Leung; Masahiro Narita; Jose M Penã; Alfredo Ponce-de-Leon; Kwonjune J Seung; Karen Shean; José Sifuentes-Osornio; Martie Van der Walt; Tjip S Van der Werf; Wing Wai Yew; Dick Menzies Journal: Clin Infect Dis Date: 2014-08-05 Impact factor: 9.079